UF investigators studied the feasibility of the immunoarray platform to screen microparticle- encapsulated adjuvant combinations for the development of improved and personalized vaccines.
UF investigators published a paper on dendritic cell activation in the Journal of Materials Chemistry B.
Two recent publications explored different methods of delivering a vaccine for type 1 diabetes, both of which prevented 40 percent of mice from developing the disease.
UFDI researcher Dr. Benjamin Keselowsky’s paper ‘Biomaterials-Based Immunomodulation of Dendritic Cells’ was featured in Laura Santambrogio, M.D., Ph.D.’s latest book, Biomaterials in Regenerative Medicine and the Immune System. You can find Dr. Santambrogio’s book here.
Benjamin Keselowsky, Ph.D., associate professor in the Department of Biodmedical Engineering, has been named a UF Research Foundation Professor for 2015-2018. Professor Keselowsky is using a $1.5M grant from the NIDDK to research novel methods for restoring cell function in Type 1 diabetes.
Benjamin Keselowsky, Ph.D. has received a new NIH R01 grant for “Biomaterial Delivery System for Type 1 Diabetes Vaccine”. Funded by the National Institute of Diabetes and Digestive and Kidney Diseases in collaboration with UF Diabetes Institute Director, Mark Atkinson, Ph.D., and Clive Wasserfall, this, $1.5M grant will fund the investigation of biodegradable microparticle/hydrogel formulations delivering immuno-modulatory factors to targeted immune cell types for the prevention and reversal of T1D.
Learn about the latest drug-delivery system developed by University of Florida researches that holds the promise for ways to treat and ultimately prevent persons from developing Type 1 Diabetes. The joint effort is bringing research closer to a cure.
